top of page
Browse by category
Search
COVID-19 pandemic: Bariatric surgery patients showed an increase in the percentage of weight regain
Two years after the start of the COVID-19 pandemic, bariatric surgery patients showed an increase in the percentage of weight regain and...
Semaglutide and liraglutide may reduce alcohol consumption in individuals with AUD
A joint study by the University of Eastern Finland and Karolinska Institutet in Sweden has found that the GLP-1 agonists semaglutide and...
NK2R burns energy and lowers appetite without the nausea and vomiting
Scientists at the University of Copenhagen have discovered a new weight loss drug target, neurokinin 2 receptor (NK2R), that reduces...
Adults with pre-diabetes and obesity or overweight treated with tirzepatide had sustained weight loss and nearly 99% remained diabetes-free at 176 weeks
Results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide,...
Helix model can predict 12-month weight loss response of semaglutide in diverse populations
Helix has unveiled new clinical research at the American Society of Human Genetics (ASHG) 2024 Annual Meeting, featuring a novel...
Journal Watch 13/11/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
IFSO Bariatric Endoscopy Committee endorses endoscopic sleeve gastroplasty as an effective and valuable treatment for obesity
The IFSO Bariatric Endoscopy Committee has endorsed endoscopic sleeve gastroplasty (ESG) as an effective and valuable treatment for...
BMS reduces obesity-related pregnancy complications but introduces potential risks that may result in adverse outcomes
Whilst bariatric and metabolic surgery (BMS) can reduce obesity-related pregnancy complications, it can inadvertently result in an...
Anaemia remains a significant condition ten years after bariatric surgery
Anaemia remains a significant but still manageable condition five and ten years after bariatric surgery, but despite the prescription of...
Ascletis' announces promising results for ASC47 adipose-targeted THRβ
Ascletis Pharma has announced that results of its Phase I single ascending dose (SAD) study in Australia in subjects with elevated...
Browse by tag
bottom of page